Skip to search formSkip to main contentSkip to account menu

MP470

Known as: HPK56, MP-470 
National Institutes of Health

Related topics

Related topics

3 relations
Amuvatinib Hydrochloride

Broader (1)

Pyrimidines

Narrower (1)

amuvatinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase Ib dose-escalation study of orally administered MP-470, a multi-kinase inhibitor and supressor of Rad51, in combination with carboplatin doublet containing regimens shows activity in highly…
e13511 Background: MP-470 (MP) is an oral multi-targeted tyrosine kinase inhibitor which inhibits a number of validated tumor… 
2013
2013
Abstract 2095: A phase 2 study of Amuvatinib (MP-470), the first RAD51 inhibitor in combination with platinum-etoposide (PE) in refractory or relapsed small cell lung cancer (ESCAPE).
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Amuvatinib is an oral multi-targeted TKI… 
2010
2010
Abstract 2749: MP-470, a dual inhibitor of mutant kinases (c-KIT and PDGFRα) and DNA repair protein Rad 51. Final results from a first-in-man single agent study
Background: MP-470 is an orally bioavailable multi-targeted tyrosine kinase inhibitor specifically designed to be a potent… 
2009
2009
Gateways to clinical trials.
(-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)